Skip to main content
. 2019 Apr;31(2):223–258. doi: 10.21147/j.issn.1000-9604.2019.02.01

S4.

Pathological TNM staging of adenocarcinoma of esophagus/esophagogastric junction (pTNM)

Stage TNM Grade
1. HGD, High-grade dysplasia.
2. Number of harvested regional lymph nodes should be more than 12 to achieve accurate staging.
3. Location (primary cancer site) is defined by position of the tumor epicenter (divided into upper, middle and lower esophagus. Upper esophagus = cervical esophagus + upper thoracic esophagus; middle esophagus = middle thoracic esophagus; lower esophagus = lower thoracic esophagus + abdominal esophagus).
4. Tumors with a midpoint in the lower thoracic esophagus, EGJ, or within the proximal 2 cm of the stomach that extends into the EGJ (Siewert types I and II) are classified as esophageal cancer for staging purposes; Tumors with a midpoint in the stomach more than 2 cm distal to the EGJ (Siewert type III) are staged using the gastric cancer staging system.
5. Basal cell-like squamous cell carcinoma, spindle cell squamous cell carcinoma, small cell carcinoma, large cell neuroendocrine carcinoma and undifferentiated carcinoma are staged as poorly differentiated squamous cell carcinoma. Mixed carcinoma with mixed squamous cell carcinoma components (e.g. adenosquamous carcinoma) or histologically unidentified carcinoma are staged as squamous cell carcinoma.
6. Neuroendocrine tumors (NET) of the esophagus are rare, and their staging is based on the TNM staging of gastrointestinal neuroendocrine tumors.
7. This stage is not suitable for non-epithelial tumors such as lymphoma, sarcoma, gastrointestinal stromal tumor and melanoma.
0 Tis (HGD) N0 M0
IA T1a N0 M0 G1
IA T1a N0 M0 GX
Ib T1a N0 M0 G2
T1b N0 M0 G1−G2
T1b N0 M0 GX
IC T1 N0 M0 G3
T2 N0 M0 G1−G2
IIA T2 N0 M0 G3
T2 N0 M0 GX
IIB T1 N1 M0 Any
T3 N0 M0 Any
IIIA T1 N2 M0 Any
T2 N1 M0 Any
IIIB T2 N2 M0 Any
T3 N1−2 M0 Any
T4a N0−1 M0 Any
IVA T4a N2 M0 Any
T4b N0−2 M0 Any
Any T N3 M0 Any
IVB Any T Any N M1 Any